Dec 14,2022

Are Pharma Companies Ready to Harness the Promises of Real-World Data?

In recent years, real-world data (RWD) has started to show its true strength as a way to gain deeper, broader, and more actionable insight into patients and their outcomes. Buy-in from clinical trial experts, data companies, healthcare providers, and regulators like the FDA has made it easier and more attractive to start integrating RWD, and the resulting real-world evidence (RWE), into the drug development process. In partnership with Impatient Health, COTA conducted in-depth, semi-structured interviews with 20 high-level executive leaders from some of the most innovative pharma companies in the world, including Pfizer, Roche, Novartis, Sanofi, and Bristol Myers Squibb.

#rwd

View Analyst & Ambassador Comments
Go to original news
Oct 05,2021

Dignity Health and Propeller Health Bring Asthma and COPD Digital Inhaler Data into EHR

Dignity Health, which is part of 21-state health system CommonSpirit Health, and Propeller Health, a leader in digital health and therapeutics for asthma and chronic obstructive pulmonary disease (COPD), announced today that they have integrated Propeller’s platform into Dignity Health’s electronic health record (EHR) system. Now, the Propeller solution can be ordered and managed through the EHR like any other medication or treatment.

COLLABORATION PARTNERSHIP

#connected device

#rwd

View Analyst & Ambassador Comments
Go to original news
Sep 21,2022

Akili Launches EndeavorRx® Expedition - A Direct-to-Patient Product Registry

Akili Interactive (“Akili”), a leading digital medicine company, today announced the EndeavorRx® Expedition product registry, which aims to obtain feedback from patients receiving the digital therapeutic, and their caregivers, to determine the real-world effectiveness of EndeavorRx. EndeavorRx is the first and only prescription video game treatment cleared by the U.S. Food and Drug Administration (FDA) and is indicated to improve attention function in 8-12 year old children diagnosed with attention-deficit/hyperactivity disorder (see full indication below).

PRODUCT

#pdt

#rwd

View Analyst & Ambassador Comments
Go to original news
Jan 11,2022

OncoHealth and Triple-S Salud of Puerto Rico Partner for Evidence-Based Cancer Treatment

OncoHealth, the leading digital health company for navigating the physical, mental and financial complexities of cancer care, has announced a multi-year partnership with Triple-S Salud, an independent licensee of the Blue Cross Blue Shield Association and Puerto Rico’s largest insurer. OncoHealth and Triple-S have been partners for over two years and today, the companies announced that they have expanded their partnership to include cancer treatment reviews for all lines of business, including 450,000 Puerto Rico Government Health Plan Vital Medicaid members. This expands the health plan’s relationship with OncoHealth, which is already managing 100% of the Triple-S Medicare Advantage population and its Federal Employee Benefits (FEHB) program. The addition of the Medicaid membership brings the entire population being served by OncoHealth to more than 634,000.

COLLABORATION PARTNERSHIP

#insurance

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Jan 01,2022

Flatiron Health Announces RWD Partnership with Japan’s NCCHE

Flatiron Health today announced a partnership with Japan’s National Cancer Center Hospital East (NCCHE) to build a real-world database of patients with gastro-intestinal cancers. Under the agreement signed with Flatiron Health K.K., real-world data (RWD) chronicling the aggregated and de-identified experiences of consented NCCHE patients will be curated into top-quality datasets for use by NCCHE to support its research and treatment decisions, and by other researchers and regulatory decision-makers to help answer previously unanswerable questions.

COLLABORATION PARTNERSHIP

#institution

#rwd

View Analyst & Ambassador Comments
Go to original news
Mar 03,2022

Reality check: Real-world evidence to support therapeutic development in hematologic malignancies

In this article in the scientific journal Blood Reviews, COTA researchers and collaborators share their views on the many sources of RWD and how to assess fit-for-purpose for use in RWE generation. They also review promising use cases for RWD, particularly for hematologic malignancies.

CLINICAL STUDY

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
May 18,2022

Miami Cancer Institute Takes Action To Address Inequities in Cancer Care with Expanded COTA, Inc. Collaboration

COTA, Inc. and Miami Cancer Institute, part of Baptist Health South Florida, announced today they are expanding their real-world data (RWD) and analytics partnership. Miami Cancer Institute will use COTA’s Real-World Analytics platform (RWA) to better understand how certain patient demographics, such as zip code, ethnicity, or other socio-economic factors, contribute to unwanted disparities in patient outcomes.

COLLABORATION PARTNERSHIP

#institution

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Jun 09,2022

AdhereTech and Massive Bio Announce AI-Enabled, Patient-Centric Oncology Solutions Partnership

Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI)-enabled patient-centric clinical trial enrollment for oncology, and AdhereTech, a leading provider of smart devices that connect patients to care with real-time interventions, announced their partnership to provide advanced, data-driven digital health technology solutions, focusing in oral oncolytic agents providing real-time integrated access to care for cancer patients to precision oncology drugs and leading-edge clinical trials. Massive Bio and AdhereTech have committed to combining their products and services to offer global, comprehensive solutions to measure, analyze and monitor precision oncology medication adherence for patients participating in clinical trials and those prescribed commercially available treatments.

COLLABORATION PARTNERSHIP

#product & service

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Jul 28,2022

A common infrastructure for real-world patient-reported symptoms: one size fits many

Researchers now advocate a broadly accessible, common infrastructure for patient-reported toxicities from all patients—in the so-called real-world—to facilitate enhanced collection of clinically meaningful and actionable data.

CLINICAL STUDY

#rwd

View Analyst & Ambassador Comments
Go to original news
Jul 06,2022

Making the Most of Real-World Data: Addressing Cancer Disparities Starts with All of Us

At the DIA 2022 Global Annual Meeting in Chicago, COTA CEO Miruna Sasu gave a keynote speech to a packed audience.

CONFERENCES

#rwd

View Analyst & Ambassador Comments
Go to original news
Subscribe to RWD